1887

Chapter 10 : Ambulatory Management of Infected Orthopedic Implants

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Ambulatory Management of Infected Orthopedic Implants, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818067/9781555811778_Chap10-1.gif /docserver/preview/fulltext/10.1128/9781555818067/9781555811778_Chap10-2.gif

Abstract:

This chapter talks about a new diagnostic and therapeutic approach based on the ambulatory management of infections to minimize the social consequences for the patient and the important economic impact for the community. Coagulase-negative staphylococci, streptococci, gram-negative aerobes, and anaerobes are the most common bacteria in late-onset prosthetic joint infections. Infections within the first few months of surgery usually present with pain, erythema, and drainage at the wound site. The combination of fleroxacin with rifampin resulted in a 41% cure rate in an foreign-body infection model. The addition of vancomycin to the fleroxacin-rifampin combination significantly increased the cure rate and the rapidity of sterilization of the foreign body. Fusidic acid can accumulate within cells, demonstrated by the fact that 7- to 10-fold intracellular compared with extracellular concentrations have been measured in human polymorphonuclear leukocytes and lymphocytes. The only antibiotics remaining active against multiresistant staphylococci and able to diffuse into the bone tissue are glycopeptides (vancomycin and teicoplanin) and co-trimoxazole. Bone marrow changes occur in patients with preexisting depleted folate stores and one recent report established that bone marrow changes occur in one case per 18,000 prescriptions. Ciprofloxacin has an excellent penetration into bone and an excellent MIC for . Ciprofloxacin alone is effective in the treatment of osteomyelitis. Salvage of infected orthopedic implants by appropriate antimicrobial strategies is feasible and the ambulatory management of such infections contributes to humanization of therapy.

Citation: Stein A, Drancourt M, Raoult D. 2000. Ambulatory Management of Infected Orthopedic Implants, p 211-230. In Waldvogel F, Bisno A (ed), Infections Associated with Indwelling Medical Devices, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818067.ch10
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Plain radiograph of a total hip prosthesis. Note the loosening of the prosthesis at the bone-cement interfaces.

Citation: Stein A, Drancourt M, Raoult D. 2000. Ambulatory Management of Infected Orthopedic Implants, p 211-230. In Waldvogel F, Bisno A (ed), Infections Associated with Indwelling Medical Devices, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818067.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818067.chap10
1. Barber, M.,, and P. M. Waterworth. 1962. Antimicrobial activity in vitro of fucidin. Lancet 1: 931 932.
2. Brause, B. D., 1989. Infected orthopedic prostheses, p. 111 127. In A. L. Bisno, and F. A. Waldvogel (cel.), Infections Associated with Indwelling Medical Devices, 1st ed. American Society Tor Microbiology, Washington, D.C.
3. Brause, B. D., 1995. Infections with prostheses in bones and joints, p. 1051 1055. In G. L. Mandell,, J. E. Bennett,, and R. Dolin (ed.). Principles and Practice of Infectious Diseases. Churchill Livingstone. New York. N.Y.
4. Brook, I.,, and E. H. Frazier. 1993. Anaerobic osteomyelitis and arthritis in a military hospital: a 10-year experience. Am. J. Med. 94: 21 28.
5. Brouqui, P.,, M. C. Rousseau,, A. Stein,, M. Drancourt,, and D. Kaoult. 1995. Treatment of Pseudomonas aeruginosa-ini'ccleci orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob. Agents Chemother. 39: 2423 2425.
6. Brown, K. N.,, and A. Pcrcival. 1978. Penetration of antimicrobials into tissue culture cells and leukocytes. Scand. Infect. Dis. 14( Suppl.): 251 260.
7. Choutet, P.,, and N. Desplaces. 1991. Les infections bacteriennes osteo-articulaires en dehors des infections a mycobacterias. Med. Mal. Infect. 21: 134.
8. Chuard, C.,, M. Herrmann,, P. Vaudaux, F. A. Waldvogel,, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35: 2611 2616.
9. Coombs, R. R. H.,, S. Mehtar. and A. P. Menday. 1987. Fusidic acid in orthopedics. Curr. Ther. Res. 42: 501 508.
10. Coombs, R. R. H.,, and A. P. Menday. 1985. Fusidic acid in orthopedic infections due to coagulase-negative staphylococci. Curr. Med. Res. Opin. 9: 587 590.
11. Craven, P. C. 1993. Treating bone and joint infections with teicoplanin: hospitalization vs. outpatient cost issues. Hasp. Formul. 28: 41 45.
12. Davey, P. G.,, D. R. Rowley,, and G. A. Phillips. 1992. Teicoplanin—home therapy for prosthetic joint infections. Eur. J. Surg. Suppl. 567: 23 25.
13. Desplaces, N.,, and J. F. Acar. 1988. New quinoloncs in the treatment of joint and bone infections. Rev. Infect. Dis. 10: 179 183.
14. Drancourt, M.,, A. Stein,, J. N. Argenson,, R. Roiron,, P. Groulier,, and D. Raoult. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39: 235 240.
15. Drancourt, M.,, A. Stein,, J. N. Argenson,, A. Zannier,, G. Curvale,, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus infected orthopedic implants. Antimicrob. Agents Chemother. 37: 1214 1218.
16. Eisenstein, B. I., 1995. Enterobacteriaceae. p. 1964 1980. In G. L. Mandell,. J. E. Bennett,, and R. Dolin (ed.), Principles ami Practice of Infections Diseases. 4th ed. Churchill Livingston, New York, N.Y.
17. Eitel, F.,, A. Bauernfeind,, and E. Lang. 1997. Teicoplanin in the therapy of bone and joint infections. Curr. Ther. Res. 51: 97 109.
18. Feldman, L. A.,, and E. S. Murphy,. 1999. Infective endocarditis, p. 297 307. In R. E. Rakel (ed.). Conn's Current Therapy. W. B. Saunders Company, Philadelphia, Pa.
19. Forsgren, A.,, and A. Bellahsène. 1985. Antibiotic accumulation in human polymorphonuclear leucocytes and lymphocytes. Scancl. J. Infect. Dis. 44( Suppl.): 16 23.
20. Galdbart, J. O.,, A. Morvan,, N. Desplaces,, and N. El Solh. 1999. Phenolypic and genomic variation among Staphylococcus epidermidis strains infecting joint prostheses. J. Clin. Microbiol. 37: 1306 1312.
21. Gentry, I. O. 1985. Treatment of skin, skin structure, bone and joint infections with ceftadizine. Am. J. Med. 79: 67 74.
22. Gerding, D. N.,, C. E. Hughes,. D. M. Bamberger,, J. Foxworth,, and T. A. Larson,. 1996. Extravascular antimicrobial distribution and the respective blood concentrations in humans, p. 835 899. In V. Lorian (ed.). Antibiotics in Laboratory Medicine. Williams & Wilkins. Baltimore. Md.
23. Goldenberg, D. L. 1998. Septic arthritis. Lancet 351: 197 202.
24. Gomis. M.,, J. Barberan,, J. Lopez-Arceo,, J. M. Pastor,, F. Lopez,, F. Ledesma,, and G. Mosconi. 1994. Teicoplanin in the treatment of staphylococcal osteomyelitis. Ann. Exp. Clin. Med. 4: 171 176.
25. Gordin, F. M.,, G. L. Simon,, C. B. Wofsy,, and J. Mills. 1984. Adverse reactions to trimethoprim-sulfamethoxazole in patients with acquired immunodeficiency syndrome. Ann. Intern. Med. 100: 495 499.
26. Goulet, J. A.,, P. M. Pellicci,, B. D. Brause,, and E. M. Salvati. 1988. Prolonged suppression of infection in total hip arthroplasty. J. Arthroplasty 3: 109 116.
27. Graninger, W.,, C. Wenish,, E. Wiesinger,, M. Menschik,, J. Karimi,, and E. Presterl. 1995. Experience with outpatient intravenous teicoplanin therapy lor chronic osteomyelitis. Eur. J. Clin. Microbiol. Infect. Dis. 14: 643 647.
28. Greenberg, R. N. 1990. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin. Antimicrob. Agents Chemother. 34: 2392 2397.
29. Gristina, A. G. 1994. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin. Orthop. 298: 106 118.
30. Gristina, A. G.,, and J. W. Costerton. 1985. Bacterial adherence to biomaterials and tissue. J. Bone Joint Surg. 67-A: 264 273.
31. Imman, R. D.,, K. V. Gallegos,, B. D. Brause,, P. B. Redecha,, and C. L. Christian. 1984. Clinical and microbiological features of prosthetic joint infection. Am. J. Med. 77: 47 53.
32. Jansen, K. 1968. Melhicillin-resistant staphylococci. Lancet ii: 1078.
33. Jett, B.,, M. M. Huycke,, and M. Gilmore. 1994. Virulence of enterococci. Clin. Microbiol. Rev. 7: 462 478.
34. Karchmer, A. W. 1998. Editorial response: salvage of infected orthopedic devices. Clin. Infect. Dis. 27: 714 715.
35. Keisu, M.,, B. E. Wilholm,, and J. Palmblad. 1990. Triniethoprim-sulfamethoxazole-associated blood dyspasias. Ten years experience of the Swedish spontaneous reporting system. J. Intern. Med. 228: 353 356.
36. Lefrock, J. L.,, A. M. Ristuccia,, P. A. Ristuccia,, R. W. Quenzer,, P. G. Haggerty,, J. E. Allen,, L. A. Lettau,, R. Schwartz,, and D. Appelby. 1992. Teicoplanin in the treatment of bone and joint infections. Acta Chir. 567: 9 13.
37. Lefrock, J. L.,, A. M. Ristuccia,, P. A. Ristuccia,, R. W. Quenzer,, P. G. Haggerty,, J. E. Allen,, L. A. Lettau,, R. Schwartz,, and D. Appelby. 1992. Teicoplanin in the treatment of bone and joint infections. Eur. J. Surg. Suppl. 567: 9 13.
38. Mandell, G. L. 1983. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev. Infect. Dis. 5: S463 S467.
39. Marone, P.,, E. Concia,, M. Andreoni,, F. Suter,, and M. Cruciani. 1990. Treatment of bone and soft tissue infections with teicoplanin. J. Antimicrob. Chemother. 25: 435 439.
40. Marple, P. A. C.,, J. M. T. Hamilton-Miller,, and W. Brumfitt. 1989. World-wide antibiotic resistance in melhicillin-resistant Staphylococcus aureus. Lancet i: 537 540.
41. Masur, H., 1995. Management of opportunistic infections associated with HIV infection, p. 1280 1294. In G. L. Mandell,. J. E. Bennett,, and R. Dolin (ed.). Principles and Practice of Infectious Diseases. Churchill Livingstone, New York, N.Y.
42. Maurin, M.,, and D. Raoull,. 1993. Antibiotic penetration within eukaryotic cells, p. 21 37. In D. Raoult (ed.). Antimicrobial Agents and Intracellular Pathogens.
43. Maurin, M.,, and D. Raoult. 1994. Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin. J. Infect. Dis. 169: 330 336.
44. Maurin, M.,, and D. Raoult. 1997. Intracellular organisms. Int. J. Antimicrob. Agents 9: 61 70.
45. Melchior, N. H., 1985. Combined in vitro activity of fusidic acid and rifampicin against melhicillin-resistant Staphylococcus aureus strains, p. 137 147. In J. Ishigami (ed.). Recent Advances in Chemotherapy, Antimicrobial Section I. Proceedings of the 14th International Congress of Chemotherapy. University of Tokyo. Press, Tokyo. Japan.
46. Michel, M.,, and L. Gutmann. 1997. Methicillin-resislant Staphylococcus aureus and vancomycin-resistanl enterococci: therapeutic realities and possibilities. Lancet 349: 1901 1906.
47. Moellering, R. C., Jr. 1997. Emergence of Enterococcus as a significant pathogen. Clin. Infect. Dis. 14: 1173 1176.
48. Murray, B. E. 1990. The life and times of Enterococcus. Clin. Microbiol. Rev. 3: 46 65.
49. Nakata, M. M.,, and R. P. Lewis. 1984. Anaerobic bacteria in bone and joint infections. Rev. Infect. Dis. 6: S165 SI70.
50. Nicoletti, G.,, and S. Stefani. 1995. Enterococci: susceptibility patterns and therapeutic options. Eur. J. Clin. Microbiol. Infect. Dis. 14( Suppl. 1): 33 37.
51. Nix D. E.,, T. J. Cumbo,, P. Kuritzky,, J. M. Devito,, and J. J. Schentag. 1987. Oral ciprofloxacin in the treatment of serious soli tissue and bone infections: effieacity. safely, and pharmacokinetics. Am. J. Med. 82: 146 153.
52. Norden C. W.,, J. Fierer,, E. Bryant, and Chronic Staphylococcal Osteomyelitis Study Group. 1983. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev. Infect. Dis. 5: 495 501.
53. Norden, C. W.,, and E. Keleti. 1980. Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination. Antimicrob. Agents Chemother. 17: 591 594.
54. Norden, C. W.,, and M. Shaffer. 1983. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J. Infect. Dis. 147: 352 357.
55. Proctor, R. A.,, and G. Peters. 1998. Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. Clin. Infect. Dis. 27: 419 423.
56. Proctor, R. A.,, P. Van Langevelde,, M. Kristjansson,, J. N. Maslow,, and R. D. Arbeit. 1995. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin. Infect. Dis. 20: 95 102.
57. Proctor, R., 1994. Microbial pathogenic factors: small colony variants, p. 79 90. In A. L. Bisno, and F. A. Waldvogel (ed.). Infections Associated with Indwelling Medical Devices. 2nd ed. ASM Press, Washington, D.C.
58. Raymond, N. J.,, J. Henry,, and K. A. Workowski. 1995. Enterococcal arthritis: case report and review. Clin. Infect. Dis. 21: 516 522.
59. Richardson, J. F.,, and R. R. Marples. 1980. Differences in antibiotic susceptibility between Staphylococcus epidermidis and Staphylococcus saprophyticus. J. Antimicrob. Chemother. 6: 499 510.
60. Rowling, D. E. 1970. Further evidence in the management of chronic osteomyelitis. J. Bone Joint Surg. 52-A: 302 307.
61. Rubinstein, E. 1993. Cost implications of home care on serious infections. Hosp. Formul. 28: 46 50.
62. Saleh Mghir, A.,, A. C. Cremieux,, R. Bleton,, F. Ismael,, M. Manteau,, S. Dautrey,, L. Massias,, L. Garry,, N. Sales,, B. Maziere,, and C. Carbon. 1998. Efficacy of teicoplanin and autoradiographic diffusion pattern ol [ 14C] teicoplanin in experimental Staphylococcus aureus infection of joint prostheses. Antimicrob. Agents Chemother. 42: 2830 2835.
63. Salvati, E. A.,, R. P. Robinson,, S. M. Zeno,, B. L. Koslin,, B. D. Brause,, and P. D. Wilson. 1982. Infection rates after 3175 total hip and total knee replacements performed with and without a horizontal unidirectional filtered air-flow system. J. Bone Joint Surg. 64-A: 525 535.
64. Sattler, F. R.,, R. Cowan,, D. M. Nielsen,, and J. Ruskin. 1988. Trimethoprim-sulfamethoxazole compared with pentamidine lor treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann. Intern. Med. 109: 280 287.
65. Schaad, H. J.,, C. Chuard,, P. Vaudaux,, F. A. Waldvogel,. and D. P. Lew. 1994. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resislant Staphylococcus aureus. Antimicrob. Agents Chemother. 38: 1703 1710.
66. Schaberg, D. R.,, D. H. Culver,, and R. P. Gaynes. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91( Suppl. 3B): 72S 75S.
67. Segreti, J.,, J. A. Nelson,, and G. M. Trenbolme. 1998. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin. Infect. Dis. 27: 711 713.
68. Shalit, I.,, S. A. Berger,, A. Gorea,, and H. Frimerman. 1989. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob. Agents Chemother. 33: 593 594.
69. Shanson, D. C. 1990. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus. J. Antimicrob. Chemother. 25( Suppl. B): 15 21.
70. Solberg, C. O.,, A. Halstensen,. and A. Digranes. 1983. Penetration of antibiotics into human leukocyte dermal suction blisters. Rev. Infect. Dis. 5: 473.
71. Stein, A.,, J. F. Bataille,, M. Drancourt,, G. Curvale,, J. N. Argenson,, P. Groulier,, and D. Raoult. 1998. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob. Agents Chemother. 42: 3086 3091.
72. Sulkowski, M. S.,, I. Z. Abolnik,, E. I. Morris,, and D. L. Granger. 1994. Infectious arthritis due to Propionibaclerium acnes in a prosthetic joint [letter]. Clin. Infect. Dis. 19: 224 225.
73. Thornsberry, C. 1985. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria. Am. J. Med. 79( Suppl. 2A): 14 20.
74. Tjandramaga, T. B.,, L. Verbist,, L. De Lepeleire,, R. Verbesselt,, and P. J. De Schepper. 1986. Intravenous teicoplanin once daily treatment: multiple dose kinetics and steady state profile. Acta Pharm. Toxicol. 59( Suppl.): 294.
75. Tobin, E. H. 1999. Prosthetic joint infections: controversies and clues. Lancet 353: 770 771.
76. Tshefu, X. 1997. Short-term administration of rifampin in the prevention or eradication of infection due to foreign bodies. Rev. Infect. Dis. 5( Suppl. 3): S468 S473.
77. Tsukayama, D.,, B. Wicklund,, and R. Gustilo. 1991. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics 14: 841 844.
78. Turnidge, J.,, and L. Grayson. 1993. Optimum treatment of staphylococcal infections. Drugs 45: 353 366.
79. Verbist, L. 1990. The antimicrobial activity of fusidic acid. J. Antimicrob. Chemother. 25: 1 5.
80. Verbist, L.,, T. B. Tjandramaga,, B. Hendrickx,. A. Vanhecken,, P. Van Nelle,, R. Verbesselt,. J. Verhaegen,, and P. J. De Schepper. 1997. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob. Agents Chemother. 26: 881 886.
81. Widmer, A. F.,, R. Frei,, Z. Rajacic,, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162: 96 102.
82. Widmer, A. F.,, A. Gaechter,, P. E. Ochsner,, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Inject. Dis. 14: 1251 1253.
83. Wiedemann, B.,, and B. A. Atkinson,. 1991. Susceptibility to antibiotics: species incidence and trends, p. 1055. In V. Lorian (ed.). Antibiotics in Laboratory Medicine. Williams & Wilkins, Baltimore, Md.
84. Winkler, G., and Weinberg. 1993. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial. South Med. 86: 891 897.
85. Yancey, R. J.,, M. S. Sanchez,, and C. W. Ford. 1991. Activity of antibiotics against Staphylococcus aureus within polymorphonuclears. Eur. J. Clin. Microbiol. Infect. Dis. 10: 107 113.
86. Zannier, A.,, M. Drancourt,, J. P. Franceschi,, J. M. Aubaniac,, and D. Raoult. 1991. Interct dune technique de lyse cellulaire par choc thermique dans I'isolcment des bacterics responsables d'infections osteo-articulaires. Pathol. Biol. 39: 543 546.
87. Zimmerli, W.,, A. F. Widmer,. M. Blatter, R. Frei,, and P. E. Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. A randomized controlled trial. JAMA 279: 1537 1541.
88. Zinner, S. H.,, and K. H. Mayer,. 1995. Sulfonamides and trimethoprim, p. 354 364. In G. L. Mandell,. J. E. Bennett,, and R. Dolin (ed.). Principles and Practice of Infectious Diseases. Churchill Livingstone, New York, N.Y.
89. Ziza, J. M.,, N. Desplaces,, P. Leonard,, and P. Mamoudy. 1997. Infections sur protheses articulaires. Rev. Med. Intern. 18: 431 434.

Tables

Generic image for table
Table 1

Interpretation and strategy determined by microbiology of sample and antibiotic activity of sample and urine

Citation: Stein A, Drancourt M, Raoult D. 2000. Ambulatory Management of Infected Orthopedic Implants, p 211-230. In Waldvogel F, Bisno A (ed), Infections Associated with Indwelling Medical Devices, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818067.ch10
Generic image for table
Table 2

Cure rates of the ofloxacin-rifampin combination for patients with infected orthopedic devices

Citation: Stein A, Drancourt M, Raoult D. 2000. Ambulatory Management of Infected Orthopedic Implants, p 211-230. In Waldvogel F, Bisno A (ed), Infections Associated with Indwelling Medical Devices, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818067.ch10
Generic image for table
Table 3

Cure rates of the fusidic acid-rifampin combination for patients with infected orthopedic devices

Citation: Stein A, Drancourt M, Raoult D. 2000. Ambulatory Management of Infected Orthopedic Implants, p 211-230. In Waldvogel F, Bisno A (ed), Infections Associated with Indwelling Medical Devices, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818067.ch10
Generic image for table
Table 4

Cure rates of co-trimoxazole for intention-to-treat patients with infected orthopedic devices

Citation: Stein A, Drancourt M, Raoult D. 2000. Ambulatory Management of Infected Orthopedic Implants, p 211-230. In Waldvogel F, Bisno A (ed), Infections Associated with Indwelling Medical Devices, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818067.ch10

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error